138 related articles for article (PubMed ID: 30782054)
1. Long-term treatment with testosterone undecanoate injections in men with hypogonadism alleviates erectile dysfunction and reduces risk of major adverse cardiovascular events, prostate cancer, and mortality.
Saad F; Caliber M; Doros G; Haider KS; Haider A
Aging Male; 2020 Mar; 23(1):81-92. PubMed ID: 30782054
[No Abstract] [Full Text] [Related]
2. Effect of Testosterone Replacement Therapy on Sexual Function and Hypogonadal Symptoms in Men with Hypogonadism.
Pencina KM; Travison TG; Cunningham GR; Lincoff AM; Nissen SE; Khera M; Miller MG; Flevaris P; Li X; Wannemuehler K; Bhasin S
J Clin Endocrinol Metab; 2024 Jan; 109(2):569-580. PubMed ID: 37589949
[TBL] [Abstract][Full Text] [Related]
3. EMAS position statement: Testosterone replacement therapy in older men.
Kanakis GA; Pofi R; Goulis DG; Isidori AM; Armeni E; Erel CT; Fistonić I; Hillard T; Hirschberg AL; Meczekalski B; Mendoza N; Mueck AO; Simoncini T; Stute P; van Dijken D; Rees M; Lambrinoudaki I
Maturitas; 2023 Dec; 178():107854. PubMed ID: 37845136
[TBL] [Abstract][Full Text] [Related]
4. Symptomatic benefits of testosterone treatment in patient subgroups: a systematic review, individual participant data meta-analysis, and aggregate data meta-analysis.
Hudson J; Cruickshank M; Quinton R; Aucott L; Wu F; Grossmann M; Bhasin S; Snyder PJ; Ellenberg SS; Travison TG; Brock GB; Gianatti EJ; van der Schouw YT; Emmelot-Vonk MH; Giltay EJ; Hackett G; Ramachandran S; Svartberg J; Hildreth KL; Antonic KG; Tenover JL; Tan HM; Ho Chee Kong C; Tan WS; Marks LS; Ross RJ; Schwartz RS; Manson P; Roberts SA; Skovsager Andersen M; Velling Magnussen L; Aceves-Martins M; Gillies K; Hernández R; Oliver N; Dhillo WS; Bhattacharya S; Brazzelli M; Jayasena CN
Lancet Healthy Longev; 2023 Oct; 4(10):e561-e572. PubMed ID: 37804846
[TBL] [Abstract][Full Text] [Related]
5. Major cardiovascular disease risk in men with testosterone deficiency (hypogonadism): appraisal of short, medium and long-term testosterone therapy - a narrative review.
Traish AM
Sex Med Rev; 2023 Sep; 11(4):384-394. PubMed ID: 37587664
[TBL] [Abstract][Full Text] [Related]
6. A practical guide to male hypogonadism in the primary care setting.
Dandona P; Rosenberg MT
Int J Clin Pract; 2010 May; 64(6):682-96. PubMed ID: 20518947
[TBL] [Abstract][Full Text] [Related]
7. TRACK_9: Testosterone replacement assessment: Classical vs. functional hypogonadism‐knowledge from a 9‐year study.
Zitzmann M; Cremers JF; Krallmann C; Soave A; Kliesch S
Andrology; 2024 Mar; ():. PubMed ID: 38488343
[TBL] [Abstract][Full Text] [Related]
8. Erythrocytosis Following Testosterone Therapy.
Ohlander SJ; Varghese B; Pastuszak AW
Sex Med Rev; 2018 Jan; 6(1):77-85. PubMed ID: 28526632
[TBL] [Abstract][Full Text] [Related]
9. Hypogonadism in hemodialysis patients: a first snapshot of prevalence and predictive factors in Tunisian patients.
Ati N; El Ati Z; Bannour I; Sallem A; Sghaier A; Bouchahda H; Zantour B; Bouzidi H; Binous MY
Pan Afr Med J; 2023; 46():63. PubMed ID: 38282781
[TBL] [Abstract][Full Text] [Related]
10. Novel perspectives of testosterone therapy in men with functional hypogonadism: traversing the gaps of knowledge.
Groti Antonič K; Zitzmann M
Aging Male; 2024 Dec; 27(1):2296460. PubMed ID: 38149634
[TBL] [Abstract][Full Text] [Related]
11. Testosterone therapy and the risk of cardiovascular disease in older, hypogonadal men.
Krishnan S; Aldana-Bitar J; Golub I; Ichikawa K; Shabir A; Bagheri M; Hamidi H; Benzing T; Kianoush S; Budoff MJ
Prog Cardiovasc Dis; 2024; 84():14-18. PubMed ID: 38423237
[TBL] [Abstract][Full Text] [Related]
12. Testosterone therapy in females is not associated with increased cardiovascular or breast cancer risk: a claims database analysis.
Agrawal P; Singh SM; Hsueh J; Grutman A; An C; Able C; Choi U; Kohn J; Clifton M; Kohn TP
J Sex Med; 2024 Apr; 21(5):414-419. PubMed ID: 38459625
[TBL] [Abstract][Full Text] [Related]
13. The role of male hypogonadism, aging, and chronic diseases in characterizing adult and elderly men with erectile dysfunction: a cross-sectional study.
Lisco G; Triggiani V; Bartolomeo N; Ramunni MI; Pelusi C; De Pergola G; Guastamacchia E; Jirillo E; Giagulli VA
Basic Clin Androl; 2023 Apr; 33(1):5. PubMed ID: 37020191
[TBL] [Abstract][Full Text] [Related]
14. Association of the extent of therapy with prostate cancer in those receiving testosterone therapy in a US commercial insurance claims database.
Lopez DS; Huang D; Tsilidis KK; Khera M; Williams SB; Urban RJ; Panagiotou OA; Kuo YF; Baillargeon J; Farias A; Krause T
Clin Endocrinol (Oxf); 2019 Dec; 91(6):885-891. PubMed ID: 31498469
[TBL] [Abstract][Full Text] [Related]
15. Association between testosterone levels and RigiScan parameters of patients with erectile dysfunction.
Yuli F; Qi Z; Haojie Y; Zedong L; Wenjie H; Runnana X; Tianhao S; Yanfei F; Bodong L
Sex Med; 2024 Feb; 12(1):qfad072. PubMed ID: 38322195
[TBL] [Abstract][Full Text] [Related]
16. Long-term Outcomes of Testosterone Treatment in Men: A T4DM Postrandomization Observational Follow-up Study.
Handelsman DJ; Grossmann M; Yeap BB; Stuckey BGA; Shankara-Narayana N; Conway AJ; Inder WJ; McLachlan RI; Allan C; Jenkins AJ; Jesudason D; Bracken K; Wittert GA
J Clin Endocrinol Metab; 2023 Dec; 109(1):e25-e31. PubMed ID: 37623257
[TBL] [Abstract][Full Text] [Related]
17. Burden of Male Hypogonadism and Major Comorbidities, and the Clinical, Economic, and Humanistic Benefits of Testosterone Therapy: A Narrative Review.
Yeo S; Holl K; Peñaherrera N; Wissinger U; Anstee K; Wyn R
Clinicoecon Outcomes Res; 2021; 13():31-38. PubMed ID: 33488103
[TBL] [Abstract][Full Text] [Related]
18. Metformin and testosterone replacement therapy inversely associated with hormone-associated cancers (prostate, colorectal and male breast cancers) among older White and Black men.
Lopez DS; Malagaris I; Polychronopoulou E; Tsilidis KK; Milani SA; Kristen Peek M; Villasante-Tezanos A; Alzweri L; Baillargeon J; Kuo YF; Canfield S
Clin Endocrinol (Oxf); 2022 Dec; 97(6):792-803. PubMed ID: 35902376
[TBL] [Abstract][Full Text] [Related]
19. Men with erectile dysfunction (ED) should be screened for cardiovascular risk factors - Cost-benefit considerations in Swiss men.
Kalka C; Keo HH; Ingwersen M; Knoechel J; Hoppe H; Do DD; Schumacher M; Diehm N
Vasa; 2024 Jan; 53(1):68-76. PubMed ID: 38047756
[No Abstract] [Full Text] [Related]
20. Addressing male sexual and reproductive health in the wake of COVID-19 outbreak.
Sansone A; Mollaioli D; Ciocca G; Limoncin E; Colonnello E; Vena W; Jannini EA
J Endocrinol Invest; 2021 Feb; 44(2):223-231. PubMed ID: 32661947
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
